Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHP-303 in healthy overweight or obese subjects
NCT03775278Phase 1Completed
- Sponsor
- pH Pharma Co., Ltd.
- Start
- Dec 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing PHP-303 with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events up to 12 weeks, Number of patients with abnormal ECG up to 12 weeks and 8 more. Started Dec 2018; status: completed.
02
Drugs
PHP-303
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03775278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775278.